Heparin attenuates TNF-α induced inflammatory response through a CD11b dependent mechanism

Gut

Volumn 47, Issue 1, 2000, Pages

  Salas, A ^a   Sans, M ^a   Soriano, A ^a   Pique J M ^a   Panes J ^a   Reverter, J C ^a   Anderson, D C ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Discovery Research   (United States)

Author keywords

CD11; ICAM 1; Inflammatory bowel disease; L selectin; P selectin; VCAM 1

Indexed keywords

CD11B ANTIGEN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LEUKOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION INHIBITION; MALE; MESENTERIC VEIN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPILLARY PERMEABILITY; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEPARIN; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MESENTERIC VEINS; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033945430     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.1.88     Document Type: Article

References (38)

1. 1 Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-3.
2. 2 Gaffney P, Gaffney A. Heparin therapy in refractory ulcerative colitis - an update. Gastroenterology 1996;110:A913.
3. 3 Evans RC, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin. A report of nine cases. Gut 1995;37:A49.
4. 4 Brazier F, Yzet T, Duchmann JC, et al. Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel diseases. Gastroenterology 1996;110: A872.
5. 5 Brazier F, Yzet T, Boruchowicz A, et al. Treatment of ulcerative colitis with heparin. Gastroenterology 1996;110: A872.
6. 6 Dupas JL, Brazier F, Yzet T, et al. Treatment of active Crohn's disease with heparin. Gastroenterology 1996;110: A900.
7. 7 Folwaczny C, Spannagl M, Wiebecke W, et al. Heparin in the treatment of highly active inflammatory bowel disease (IBD) (Abstract). Gastroenterology 1996;110:A908.
8. 8 Dwarakanath AD, Yu LG, Brookes C, et al. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-8.
9. 9 Fries W, Pagiaro E, Canova E, et al. The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat. Aliment Pharmacol Ther 1998;12:229-36.
10. 10 Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9.
11. 11 Mazlam MZ, Hodgson HJ, Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33:773-8.
12. 12 D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-34.
13. 13 Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-8.
14. 14 Lantz M, Thysell H, Nilsson E, et al. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991;88:2026-31.
15. 15 Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995;16:198-204.
16. 16 Hocking D, Ferro TJ, Johnson A. Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992;72:179-85.
17. 17 Darien BJ, Farced J, Centgraf KS, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998;9:274-81.
18. 18 Meyer J, Cox CS, Herndon DN, et al. Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993;21: 84-9.
19. 19 Hiebert LM, Liu JM. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 1990;83:47-51.
20. 20 Matzner Y, Marx G, Drexler R, et al. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984;52:134-7.
21. 21 Bazzoni G, Beltran NA, Mascellani G, et al. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 1993;121:268-75.
22. 22 Teixeira MM, Hellewell PG. Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 1993;110:1496-500.
23. 23 Carr J. The anti-inflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin El. Thromb Res 1979;16:507-16.
24. 24 Koenig A, Norgard SK, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-89.
25. 25 Diamond MS, Alon R, Parkos CA, et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/ CD18).J Cell Biol 1995;130:1473-82.
26. 26 Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997;3:414-20.
27. 27 Henninger DD, Panes J, Eppihimer M, et al. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 1997;158:1825-32.
28. 28 Walter UM, Ayer LM, Wolitzky BA, et al. Characterization of a novel adhesion function blocking monoclonal antibody to rat/mouse P-selectin generated in the P-selectin-deficient mouse. Hybridoma 1997;16:249-57.
29. 29 Tamatani T, Miyasaka M. Identification of monoclonal antibodies reactive with the rat homolog of ICAM-1, and evidence for a differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells. Int Immunol 1990;2:165-71.
30. 30 Sanz MJ, Hartnell A, Chisholm P, et al. Tumor necrosis factor alpha-induced eosinophil accumulation in rat skin is dependent on alpha4 integrin/vascular cell adhesion molecule-1 adhesion pathways. Blood 1997;90:4144-52.
31. 31 Ma L, Raycroft L, Asa D, et al. A sialoglycoprotein from human leukocytes functions as a ligand for P-selectin. J Biol Chem 1994;269:27739-46.
32. 32 Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramine. Biochem Biophys Res Commun 1978;80:849-56.
33. 33 Morise Z, Komatsu S, Fuseler JW, et al. ICAM-1 and P-selectin expression in a model of NSAID-induced gastropathy. Am J Physiol 1998;274:246-52.
34. 34 Panes J, Gerritsen ME, Anderson DC, et al. Apigenin inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation in vivo. Microcirculation 1996;3: 279-86.
35. 35 Sans M, Panés J, Ardite E, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 1999;116:874-83.
36. 36 Panes J, Perez-del-Pulgar S, Casadevall M, et al. Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology 1999;30:445-53.
37. 37 Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 1993;120:545-56.
38. 38 Ley K, Bullard DC, Arbones ML, et al. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J Exp Med 1995;181:669-75.